|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Alkermes
gptkb:Aristada
|
|
gptkbp:acquisition
|
gptkb:Elan_Drug_Technologies
gptkb:Acorda_Therapeutics
gptkb:Neuro_Rx
gptkb:Sage_Therapeutics
VIVUS, Inc.
Astra Zeneca's rights to Vivitrol
Rodin Therapeutics
|
|
gptkbp:ceo
|
Richard Pops
|
|
gptkbp:clinical_trial
|
Phase 3 trials
ALKS 2680
ALKS 3831
ALKS 5461
ALKS 8700
|
|
gptkbp:employees
|
~1,000
|
|
gptkbp:focus
|
Central Nervous System disorders
|
|
gptkbp:founded
|
gptkb:1987
|
|
gptkbp:founder
|
Richard Pops
|
|
gptkbp:headcount
|
~1,000
|
|
gptkbp:headquarters
|
gptkb:Dublin,_Ireland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alkermes, Inc.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:location
|
gptkb:Cambridge,_Massachusetts
|
|
gptkbp:market_cap
|
~$4 billion (2021)
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:Takeda_Pharmaceutical_Company
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Horizon_Therapeutics
gptkb:Merck_&_Co.
gptkb:Amgen
gptkb:Otsuka_Pharmaceutical
gptkb:Eli_Lilly_and_Company
gptkb:Novartis
gptkb:Nant_Kwest
|
|
gptkbp:products
|
gptkb:Vivitrol
gptkb:Aristada
|
|
gptkbp:research_focus
|
gptkb:Schizophrenia
gptkb:Depression
gptkb:Multiple_Sclerosis
Pain management
Addiction treatment
|
|
gptkbp:revenue
|
$1.1 billion (2020)
|
|
gptkbp:subsidiary
|
Alkermes Pharma Ireland Limited
|
|
gptkbp:symbol
|
ALKS
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.alkermes.com
|